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RESUMEN
Ácido docosahexaenoico (DHA), esencialidad y
requerimientos: porqué y cómo proporcionar (o
suministrar) la suplementación.
Los lípidos comprenden entre el 50-60% de la estructura
del cerebro, y el ácido docosahexaenoico (C22:6, DHA) es el
ácido graso poliinsaturado de cadena larga de los fosfolípidos
del cerebro más importante, siendo el 25% del total de los áci-
dos grasos. La mayor parte del DHA presente en el cerebro se
incorpora durante el desarrollo de este, el que comienza a la
26ava semana gestacional, generando una alta demanda por el
ácido graso hasta los dos años de edad. El DHA se requiere
en el desarrollo cerebral durante la diferenciación neuronal y
glial, y durante la mielinización y la sinaptogénesis neuronal.
El ácido graso debe ser incorporado a los lípidos del cerebro
preformado ya que menos de un 5% de su precursor, el ácido
alfa linolénico (LNA), se convierte a DHA. El feto humano tie-
ne una capacidad muy limitada para sintetizar DHA a partir de
LNA, por lo cual debe ser aportado por fuentes de origen ma-
terno. El DHA puede ser aportado por la madre a partir de tres
fuentes principales; desde el tejido adiposo, cual es el princi-
pal reservorio del ácido graso, a partir de la biosíntesis desde
el precursor LNA, la que ocurre principalmente en el hígado,
o como ácido graso preformado proveniente de la dieta. Du-
rante el período postnatal, el DHA es aportado por la madre al
recién nacido a través de la leche. La nutrición occidental
aporta baja cantidad de LNA y de DHA, y los Comités de Ex-
pertos en Nutrición sugieren que la madre debe recibir una
suplementación con DHA durante el embarazo y la lactancia.
Actualmente, la suplementación con DHA puede ser aportada
a partir de diferentes fuentes; como DHA puro, como un etil
éster, como aceite obtenido de microalgas, a partir de los fos-
folípidos de la yema de huevo, o en la forma de un sn-2 mo-
noacilglicerol. En esta revisión se discute sobre la evidencia
que apoya la suplementación del recién nacido con DHA, la
necesidad de la suplementación de la madre durante el em-
barazo y la lactancia, y sobre cuales son al presente las alter-
nativas para proveer la suplementación con DHA.
PALABRAS-CLAVE: Ácido docosahexaenoico - Desarro-
llo cerebral - Fuentes de ácido docosahexaenoico - Suple-
mentación con ácido docosahexaenoico.
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important omega-3 long-chain polyunsaturated fatty acid in the
brain phospholipids comprizing 25% of the total fatty acids of
the grey matter. The majority of the DHA present in the human
brain is incorporated during the brain growth spurt which starts
at week 26 of gestation and imposes a high demand for the
fatty acid until about 2 years of age. DHA is required during
brain development when neuronal and glial differentiation and
migration, and active myelination and synaptogenesis take
place. The fatty acid must be incorporated into the brain lipids
as preformed DHA because less than 5% of its precursor
(alpha linolenic acid, LNA) is converted to DHA. The human
foetus has a limited ability to synthesize DHA from LNA, and
therefore it must be largely supplied from maternal sources.
Maternal DHA available for foetal nutrition can be provided from
three main sources: adipose tissue, which is the main reservoir
for the fatty acid; through biosynthesis from the precursor LNA,
which occurs mainly in the liver; and as preformed DHA from
dietary sources. In the postnatal period DHA is provided by the
mother to the newborn through milk secretion. Western
nutrition provides low LNA and DHA and Expert Nutrition
Committees suggest that mothers should receive DHA
supplementation during pregnancy and lactation. At present
DHA supplementation can be provided from different sources:
as purified free DHA, as an ethyl ester derivative, extracted
from single-cell algae oils, from egg yolk phospholipids, or in
the form of sn-2 DHA monoacylglycerol. In this review we revise
and discuss the evidence of DHA requirements for the
newborn, the need for maternal supplementation during
pregnancy and nursing, and the alternatives at present for
providing DHA supplementation.
KEY-WORDS: Docosahexaenoic acid - Brain development
- Docosahexaenoic acid supplementation - Docosahexaenoic
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1. INTRODUCTION
Second to adipose tissue, the brain is the most
lipid-containing organ in the body. Lipids comprize
from 50-60% of the structural matter of the brain on
a dry weight basis, or 10% on a weight/weight basis
(Sastry, 1985) and seventy percent of energy during
fetal growth is devoted to brain development
(Crawford, 2000). The average adult female and
male brains weigh 1.25kg and 1.4kg, respectively
(Cockburn, 2003). At birth the full term infant human
brain weighs about 350g. However, a premature
infant born at 24 weeks has an average brain weight
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of only 100g. During the first year of life, the full
term infant brain weight increases by 750g to a
total weight of 1.1kg. Approximately 47% of this
increase in brain weight takes place in the cerebral
cortex. The cortical dry weight increase is 125g, of
which 75g are lipids, predominantly phospholipids
(Cockburn, 1999). Phospholipids make up about
one quarter of the solid mater of the brain and are
integral to the vascular system on which the brain
depends. The major phospholipids in neuronal
membranes are phosphatidylcholine (PC),
phosphatidylethanolamine (PE), phosphatidylserine
(PS), and phosphatidylinositol (PI), In addition to
phospholipids, there are also sphingomyelins
(phosphosphingolipids) and cerebrosides
(glycosphingolipids). PC confers structural stability
to neuronal membranes (Culliss & DeKrui., 1979),
while carboxyl groups of PS function as ion-
exchange sites (Cook et al., 1972).
Docosahexaenoic acid (C22:6, DHA), together
with arachidonic acid (C20:4 AA) are, respectively,
the major omega-3 and omega-6 long-chain
polyunsaturated fatty acids (LC-PUFA) in the
mammalian brain and in retinal phospholipids, a
tissue that from the phylogenetic point of view can
be considered of neural origin (Jeffrey et al., 2001).
DHA constitutes approximately 25% of the total
fatty acids of the phospholipids of the gray matter
and 50% of the fatty acids in retinal rod outer
segments, which represent almost the only
polyunsaturated fatty acid (Anderson, 1970). DHA
preferentially cross-links with proteins and through
their high degree of unsaturation mediates the
activity of membrane bound enzymes at the
neuronal cells. It is believed that DHA plays an
important role in regulating the fluidity of neuronal
membranes and thus the efficiency of neuroelectrical
signal transmission (Kurlak & Stephenson, 1999).
The majority of DHA present in the human brain is
incorporated during the brain growth spurt which
starts at week 26 of gestation and imposes a high
demand for the fatty acid until about 2 years of age.
DHA is required during brain development when
neuronal and glial differentiation and migration, and
active myelination and synaptogenesis take place.
Neuronal differentiation and migration are essentially
prenatal processes (Jumpsen et al., 1997), but
gliogenesis, neuronal myelination and synaptogenesis
are predominantly postnatal events occurring in the
first 18 months of postnatal life (Morgane et al.,
1993). DHA together with AA are highly conserved
LC-PUFA in the brain because less than 15% of
these fatty acids is beta oxidized, in contrast to
alpha linolenic acid (C18:3, omega-3, LNA) the
precursor of DHA, and of linoleic acid (C18:2,
omega-6, LA) the precursor of AA, which are
converted in a small proportion to the respective
LC-PUFA in the brain, the rest being oxidized
(Leyton et al., 1987). Preformed DHA is
incorporated directly into the developing brain in an
order of magnitude greater than synthesis from
LNA (Sinclair, 1975). Less than 5% of LNA is
converted to DHA, 5%-10% is used for the
biosynthesis of cholesterol in the brain rather than
for DHA biosynthesis and up to 80% is oxidized
(Cunnane, 2001). Once accreted in the brain, DHA
is tenaciously retained once neural development
has occurred (Salem et al., 2001).
2. ABOUT DHA ESSENTIALITY 
The foetus and the placenta are fully dependent
on the maternal LC-PUFA supply for their growth and
development. Although the major deposition of fat
occurs in the human foetus during the third trimester,
the placental vessels and the uterine vasculature are
dependent on LC-PUFA supplied by the mother for
eicosanoid and docosanoid formation from the
moment of conception. The human foetus has a
limited ability to synthesize DHA from its precursor
LNA, and therefore it must be largely supplied from
maternal sources (Cunnane, 2001). It has been
proposed that foetal elongase/desaturase enzyme
systems are immature and unable to synthesize the
required amount of DHA for brain and visual
development (Uauy et al., 2000). This failure of
synthesis may have been exacerbated by the lower
hepatic reserves of DHA associated with premature
delivery. Foetal growth represents largely drawn
upon maternal DHA stores and a limitation in the size
of the maternal omega-3 LC-PUFA stores may be
critically detrimental to foetal growth and development
(Van Houwelingen et al., 1992). Maternal DHA
available to foetal nutrition can be provided from
three main sources: adipose tissue, which is the
main reservoir for the fatty acid; through biosynthesis
from the precursor LNA, which occurs mainly in the
liver; and as preformed DHA from dietary sources.
Maternal supplies of DHA are transferred to the
foetus through the placenta, a tissue highly
permeable to LC-PUFA, and to the neonate through
breast milk which contains a small but significant
amount of DHA. The placenta plays a crucial role in
the mother-to-foetal fatty acid transport. The tissue
exerts a specific capturing and release of DHA and
AA to foetal circulation in terms that the relative
percentage of these LC-PUFA increases in
phospholipids progressively from maternal blood to
placenta and to foetal blood, liver, and brain.Through
this process, termed biomagnification (Crawford et
al., 1976), the placenta may direct and control the
specific delivery of omega-3 and omega-6 LC-PUFA
to meet the requirements of the growing foetal brain.
A placental plasma membrane binding protein that
preferentially binds LC-PUFA over nonessential fatty
acids and which favors the unidirectional flow of
maternal LC-PUFA to the foetus was described by
Dutta-Roy (2000). LNA is also transferred to the
foetus from the mother, however preformed DHA is
incorporated to foetal tissues by least one order of
magnitude higher than LNA-derived DHA (Sheaff-
Greiner et al., 1997). It has been reported that 80%
of human foetal brain DHA accrues between weeks
26 and 40 of gestation, which means that during this
gestational period the placenta must increase its
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selective capturing and release of fatty acid, and
presumably of AA.
It has been demonstrated that omega-3 and
omega-6 LC-PUFA are selectively transported from
the liver to the placenta and then to the brain in the
form of sn-2 docosahexaenyl and sn-2 arachidonyl
lysophosphatidylcholine (DHA-lysoPC and AA-
lysoPC, respectively) bound to albumin, which
appear to be a preferential form of transport over
the corresponding unesterified form (Lemaitre-
Delaunay et al., 1999). This transport appears to be
exclusive for the brain, because other organs, such
as the liver, kidney, and heart, do not exhibit such a
preference (Lagarde et al., 2001). This suggests the
existence of a recognition system of the
lysophosphatidylcholine species in the brain (Thiés et
al., 1992). However, in the brain DHA is incorporated
mainly to the sn-2 position of PS and PE, and
secondary to PC. This means that a specific
transfer of DHA must occur from DHA-lysoPC to PS
and PE. The brain vascular epithelium has the
particular ability to acylate and/or hydrolyze these
phospholipid species. PS is synthesized from pre-
existing PC and PE through a base-exchange
reaction and subsequently decarboxylated to PE by
phosphatidylserine decarboxylase (Thiés et al.,
1992). AA is also incorporated to either the sn-2 or
to the sn-3 position of PS and PC. sn-3 Position is
preferentially occupied by AA when the sn-2
position is substituted by DHA.
DHA is mostly concentrated in the phospholipids
that form neural growth cones, synaptosomes,
microsomes, and mitochondria (Suzuki et al., 1997)
and presumably is involved in the synaptic function.
AA is more regularly distributed to the total neural
membranes. The specific participation for DHA in
neuronal functions, such as vesicular storage and
the release of neurotransmitters, neurotransmitter
reuptake transporters, presynaptic and postsynaptic
receptor function, and second messenger
responsiveness, have not been extensively studied
and remain as a very fertile research field
(Fernstrom, 2000). LNA is not accreted in the brain,
but it is transported by an unidentified mechanism,
presumably similar to DHA, to glial cells where it is
elongated/desaturated to be converted to DHA, and
then transported to the neurons, which do not have
the capability to transform LNA to DHA (Moore et al.,
1991). Information about AA biosynthesis from LA to
the glial cells is not available but presumably LA may
also be transformed to AA by the same elongation/
desaturation mechanism. DHA and AA are recycled
within brain cell phospholipids independently of
each other, suggesting that recycling is regulated
independently by DHA- and AA-selective enzymes
(Contreras et al., 2001).
3. DHA REQUIREMENTS
During the third trimester of human development,
omega-3 and omega-6 LC-PUFAs accrue in fetal
tissues as essential components of brain
phospholipids. This is the period where the brain
increases in cell size, cell number, and cell type,
therefore brain lipids must be increased rapidly
during the last weeks of gestation. Although
haemato-encephalic barrier is highly permeable to
LNA and LA, these two fatty acids are not accreted
into the brain during the last trimester of pregnancy
as are their derivatives DHA and AA.This means that
the two LC-PUFAs must be accreted as preformed
fatty acids because as discussed, the foetal brain
does not have the ability to desaturate/elongate LNA
and LA to DHA and AA, respectively (Clandinin et al.,
1981). As the fetal liver, presumably, is not totally able
to meet with the brain requirements of DHA and AA
because of the immaturity of the desaturation/
elongation enzymatic system, DHA and AA must be
provided by the mother. These LC-PUFAs are
accreted at different rates during intra-uterine life
compared to extra-uterine life. Brain DHA accretion is
higher during intra-uterine life, whereas AA accretion
is higher in the post-delivery period. This means that
the higher DHA requirements are mostly produced at
the pre-natal period and therefore the fatty acid must
be provided by the mother (Clandinin, 1999). A
progressive decline in maternal LC-PUFA, which
affects more markedly to omega-3 than omega-6
fatty acids, has been observed during pregnancy.
Infants born of multiparous mothers have lower DHA
levels than those of primiparous mothers and
maternal DHA stores are not fully replenished in the
interval between successive pregnancies (Al et al.,
1995). This may be relevant in women from under
developed countries where the first pregnancy occurs
at a very young age followed by successive
pregnancies with short intervals in between which
may not allow enough time to provide the DHA
required for optimal foetal development.
During the post-natal period omega-3 and
omega-6 LC-PUFA are provided to the newborn
through milk secretion. Human milk contains a small
amount of DHA (0.2-0.4%) and AA (0.5-0.6%)
(Jensen, 1999) which are, however, enough to meet
the LC-PUFA requirements during the breastfeeding
period (Koletzko et al., 1992). Cow’s milk contains AA
but not DHA. These are one of the reasons why
cow’s milk can not replace mother’s milk during the
suckling period. When mother’s breast milk supply is
suspended or reduced, babies should be fed
formulas which contain omega-3 and omega-6 fatty
acids. Some formulas contain LNA and LA, mostly
those in the US and Canada, but others also contain
DHA and AA, such as the formulas used in Europe,
Asia and South America (Koletzko & Sinclair, 1999).
Since 2002 infant formulas with added DHA +AA for
infants born full-term and prematurely became
available in the US (Koo, 2003). The rationale for
adding LC-PUFA to infant formula was primarily
because of their presence in large quantities in brain,
the retina, and in human milk. In addition, infants who
are fed formulas containing LC-PUFAs and breastfed
infants have comparable DHA and AA levels in red
blood cells and plasma, in contrast to the lower DHA
and AA levels in those who are fed infant formulas
containing only LNA and LA (Carlson et al., 1991).
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4. THE NEED FOR DHA SUPPLEMENTATION
Since the report by Hoefer & Hardy (1929)
several studies have reported that children who are
breastfed score higher on tests of cognitive
development than children who are formula fed
(Anderson et al., 1999), and that this effect becomes
more pronounced with increasing duration of
breastfeeding (Gale & Martyn, 1996). In premature
infants, the evidence that human milk may promote
neurodevelopment and higher intellectual quotient is
stronger. Also, the association between the duration
of breastfeeding and adult intelligence has been
established (Mortensen et al., 2002). Although
human milk contains a myriad of components, some
of them not fully identified, it has been suggested
that omega-6 and omega-3 LC-PUFAs are relevant
in the development of intellectual abilities.
Recommendations to add omega-6 and omega-3
LC-PUFAs to formulas either to replace its original
composition of LNA and LA, or to increase the total
content of PUFAs and LC-PUFAs have been
proposed from different research groups. However,
is there proof of the benefits for infant development
from feeding infant formulas containing omega-6
and omega-3 LC-PUFAs? Studies comparing
children who were breastfed with children who were
fed infant formula have reported an association
between breast feeding and intellectual
development (Colombo, 2001). Several studies have
evaluated whether supplementing formulas for full-
term or premature infants with DHA increases
circulation levels of the fatty acid and enhance
cognitive, memory, and visual development (Das,
2003). Nevertheless, results are controversial. While
some researchers do not support the addition of
DHA to formulas because they have not observed
enhancement in developmental parameters during
the first months after birth, others claim improvement
in visual and or cognitive abilities after post-natal
DHA supplementation. Agostoni et al. (1997)
demonstrated a direct influence of omega-3 LC-
PUFA supplemented formula on the development
quotient of healthy, full term infants. They evaluated
neurodevelopment by the Brunet-Lézine psychomotor
development test at 4 months of age, comparing
with breast-fed infants and those fed with standard
formula. Formula-fed infants who received omega-3
LC-PUFAs supplementation and breast-fed infants
scored better than standard formula-fed infants.
They suggest that formula supplementation with
omega-3 LC-PUFAs can benefit full-term infants in
their neurodevelopmental performance. Willats et al.
(1998) assessed the cognitive behaviour of a group
of full-term infants who, for their first 4 postnatal
months had been randomized to receive a formula
supplemented and not supplemented with AA 
and DHA. At 10 months of age, the LC-PUFAs
supplemented infants performed significantly better
on the means-end problem-solving test used than
did infants who had received the non supplemented
formula. In addition, Hansen et al. (1997) found that
infants who were fed formulas enriched with DHA
and AA had improved growth relative to infants who
were fed standard formula. Contrasting to the
observation of the preceding authors, Lucas et al.
(1999) observed no evidence of a beneficial or
adverse effect on cognitive or motor development in
full-term babies who were fed formula with or
without LC-PUFAs at 18 months of age when
evaluated according to the Bayley Mental and
Psychomotor Development test. Auestad et al.
(2001) more recently observed that adding AA +
DHA to formulas does not improve growth, visual
acuity, information processing, language, or
temperament in healthy, full-term infants during the
first month after birth. Malcolm et al. (2003)
demonstrated that maternal DHA supplementation
during pregnancy did not enhance maturation of
visual evoked potential in healthy full-term infants.
However, these results show an association
between the DHA status of infants at term and early
postnatal development of the pattern-reversal visual
evoked potential, suggesting that DHA status itself
may influence maturation of the central visual
pathway.The correlation between LC-PUFAs at birth
or after some months of life and cognitive
performance at several years of life has been also
studied. Birch et al. (2000) reported no correlation
between DHA at 12 months and developmental
outcomes at 18 months. More recently Bakker et al.
(2003) do not provide evidence for a positive
association between cognitive performance at 7
years and LC-PUFAs status at birth or at 7 years.
However, as discussed by Mostofsky (2001), and
Gibson & Makrides, (2001) the experimental design,
methodologies, and environmental differences play
a central role in studies investigating the effect of
nutritional factors, such as DHA, on cognitive and
visual development during infancy. Salem et al.
(2001) in a critical review about omega-3 and
omega-6 LC-PUFA supplementation for full-term
infants concluded that “given the present state of
knowledge from human and animal studies on
changes in the neural function associated with a low
DHA status, coupled with biochemical and
nutritional studies indicating the loss of DHA in both
peripheral tissues and the nervous system when
preformed DHA is not fed, it is clear that a prudent
course of action would be to supply sources of
preformed DHA to the infant diet”. Expert Nutrition
Committees suggest that the mother should receive
DHA supplementation during pregnancy and
lactation, a daily amount of 300mg/d is the
recommended intake (Simopoulos et al., 1999).
Recently Cockburn (2003) in an exhaustive analysis
revised the role of LC-PUFAs, and of other nutrients
such as liposoluble vitamins, cholesterol, and
lecithin, in infant psychomotor development. With
respect to LC-PUFAs the author concluded that the
research does not support that adding DHA and AA
to formulae containing 10% energy as LA and 1%
energy as LNA may enhance growth, visual acuity,
information processing, general development,
language or temperament in healthy, full- term
infants during the first 14 months after birth.
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According to the information available it appears not
be possible at present to reach a consensus about
the role of LC-PUFAs on psychomotor development.
Nevertheless, there is consensus about the
importance of DHA and AA for neural system
structure and function. However, differences in
measurement of psychomotor capabilities due to the
amount of these LC-PUFAs supplied before, during,
and after the gestational period, may obey to a
metabolic “fine tuning” that some researchers are
able to measure and evaluate, but others are not.
5. DIGESTION AND ABSORPTION 
OF DHA-CONTAINING LIPIDS
The normal pathway of dietary triacylglycerol
digestion involves hydrolysis by lingual-gastric and
pancreatic lipases to form sn-2 monoacylglycerols and
unesterified fatty acids. The sn-2 monoacylglycerols
and fatty acids are absorbed into the intestinal cells,
reassembled into triacylglycerols via the sn-2
monoacylglycerol or sn-3 glycerophosphate pathways
to reform triacylglycerols and phospholipids,
respectively, assembled into chylomicrons and
secreted into the lymph (Small, 1991). The sn-2
monoacylglycerol pathway, in which fatty acids are
reesterified with little or no specificity to the glycerol
sn-1 and sn-3 position predominates in the fed state
(Thompson et al., 1989). Consequently, the distribution
of fatty acids in the dietary triacylglycerols
determines not only whether fatty acids are
absorbed as sn-2 monoacylglycerols or fatty acids
but also, in part, the subsequent position of the fatty
acids in the chylomicron triacylglycerols. The fatty
acids hydrolyzed from the sn-1 and sn-3 position of
chylomicron triacylglycerol by epithelial lipoprotein
lipase are taken up by adipose, muscle, and other
tissues to be beta-oxidized or accumulated as
triacylglycerides for subsequent energy production.
After lipoprotein lipase hydrolysis chylomicrons are
transformed into remnant chylomicrons returning to
the liver, where specific remnant chylomicron
receptors allow their entrance into the hepatic cells.
Therefore the remaining sn-2 monoacylglycerides
in chylomicrons after peripheral lipoprotein lipase
hydrolysis are directed to the liver. It has been
proposed that the most “biologically important” fatty
acids in terms of their biochemical and metabolic
requirements (i.e., the essential fatty acids) must be
esterified at the sn-2 position in triacylglycerols and
also in phospholipids to be metabolically useful
(Mortimer et al., 1998). LNA and LA in vegetable
oils are most frequently esterified at the sn-2
position of triacylglycerols. The most important
sources of DHA are marine oils, and over 80% of
DHA in these oils is substituted at the sn-2 position
of triacylglycerols and phospholipids (Sawada et
al., 1993). This means that when DHA is provided
from marine oils an important fraction of the LC-
PUFA will be transported directly to the liver to meet
its metabolic requirements. Eicosapentaenoic acid
(C20:5, EPA) which is another omega-3 LC-PUFA
involved in many important metabolic processes,
and which is an intermediary in the synthesis of
DHA (Benatti et al., 2004), is also esterified in a
high proportion at the sn-2 position of marine
triacylglycerols and phospholipids. According to
this, to obtain a good bioavailability for LC-PUFAs,
the fatty acid must be preferentially esterified at the
sn-2 position of triacylglycerols, phospholipids or
other lipids derived from these sources, as will be
further discussed.
6. HOW TO PROVIDE DHA SUPPLEMENTATION
After the suggestion of Expert Committees to
include omega-3 LC-PUFA in infant formulas, efforts
were made to identify suitable sources of DHA
supplementation. Refined and deodorized fish oil
was initially used because of its availability, relatively
high content of DHA, and the almost absence of LA
and AA. However, fish oil contains EPA which has
been implicated into adverse effect in the growth of
premature infants (Carlson et al., 1996). Also, a
concern is that all fish oils are subjected to different
levels of contamination with heavy metals and
organic components. Therefore, other sources were
developed. At present DHA supplementation can be
provided in variable amounts and degrees of purity
from different sources, such as purified free DHA or
as ethyl ester derivative, extracted from single-cell
algae oils, from egg yolk phospholipids, or as has
been recently communicated in the form of sn-2 DHA
monoacylglycerol. We discuss the advantages and
disadvantages of these DHA sources to provide
supplementation.
Free DHA and DHA-ethyl ester
Since fish oil contains a mixture of triacylglycerols
with various fatty acids, the concentration of DHA
may be relatively low (not higher than 18%).
However, higher concentrations of DHA can be
achieved from the hydrolysis of fish oil and further
separation of selected fatty acids, such as DHA or
EPA by column chromatography. Pure preparations
of DHA as free fatty acid or as DHA-ethyl ester have
been used for supplementation. Pure DHA as free
fatty acid, however, causes gastrointestinal
complaints (Beckermann et al., 1990) and is very
unstable to oxidation and difficult to incorporate into
supplementation vehicles such as milk or formulas.
In contrast to the free fatty acid, no side-effect is
induced by the ethyl ester derivative. DHA-ethyl
ester is less unstable than the free fatty acid, and
can be incorporated into a supplementation vehicle
mixed with other lipid components. DHA-ethyl ester
supplementation has been used in several
experimental protocols, both in humans and animals
(Zuijdgeest-van Leeuwen et a., 1999). However, the
absorption efficiency in the intestinal tract of the
ethyl ester-derivative is controversial. Lawson and
Hughes (1988) demonstrated that DHA-ethyl ester
is poorly absorbed (less than 20%) in humans when
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compared to the free fatty acid because ethyl esters
are poor substrates for pancreatic lipase. However,
more recently Zuijdgeest-van Leeuwen et al.,(1999),
demonstrated that orally administered omega-3 fatty
acid ethyl esters are efficiently hydrolyzed by rat
lipase and absorbed. Moreover, our group recently
demonstrated that DHA as ethyl ester may increase
plasma and erythrocyte DHA content, which is a
criterion for evaluating the LC.PUFA bioavailability
(Valenzuela et al., 2005). Also, the DHA-ester
increases the accretion of the fatty acid into the brain
of rat pups when the lipid is orally administered to the
dams (Valenzuela et al., 2005a). Plasma and
erythrocyte fatty acid content have been considered
by several authors as valid criteria to evaluate fatty
acid absorption. Clinically, DHA-ethyl ester
supplementation was successfully used by Martínez
et al., (2000), to alleviate the symptoms of some
paroxysmal child diseases that produce profound
brain deficiency of DHA, such as Zellweger syndrome
and its variants, neonatal adrenoleukodistrophy and
infantile Refsum disease, which are characterized by
metal retardation and progressive neurosensorial
deterioration (Martínez, 2001).
Single cell algae DHA-rich oil
Some marine algae produce large amounts of
DHA. The algae used in the commercial production
of DHA-rich oil are of the Crypthecodinium cohnii
strain. The manufacturing process has been
described by Becker & Kyle (1998). Briefly, the
fermentation process starts with the inoculation and
the transferring of the primary culture to
progressively larger vessels while maintaining
optimal temperature, pH, dissolved oxygen level,
and agitation. When the culture reaches the desired
cell density and fatty acid content, it is harvested by
centrifugation and spray-dried. Following this, the
DHA-rich oil is produced in the same way that most
vegetable oils are made today. The first step is
extraction of the biomass with hexane in a
continuous process, then the oil is desolventized
under vacuum, and winterized to remove the highly
saturated triacylglyceride fractions. The winterized
oil is then refined, bleached and deodorized. The
resulting clear, odourless algae oil is finally diluted
with high-oleic sunflower oil to bring the DHA level to
40%. The LC-PUFA is mainly occupying the sn-2
position of oil-triacylglycerols, which is similar to the
most frequent position of DHA in human milk. Algae
oil also contains AA which is at the sn-2 and the sn-
1 position of triacylglycerols. Antioxidants (mainly
tocopherols) are added to the oil to prevent
oxidation. Algae oil rich in DHA has been considered
as a substance “Generally Recognized as Safe
(GRAS)” with good stability and bioavailability.
Egg yolk DHA phospholipids
Egg yolk is a complex oil/water emulsion
comprising of approximately 50% water, 32% lipids,
16% protein, besides carbohydrates and minerals.
A substantial part of the egg yolk lipid fraction
(approx. 28%) is formed by phospholipids. Their
main components are PC (73%), and PE (15%). As
an ingredient egg yolk phospholipids are applied in
food systems to optimize micronutrients like
emulsions for enhanced appearance and taste of
food products. Egg yolk contains on average 0.4-
0.6% DHA, which is mainly at the sn-2 position of
PC. DHA concentration can be increased by feeding
laying hens with linseed oil, canola oil, or directly
with fish oil. Under these conditions DHA can be
increased up to 1.2-1.5% (120-150 mg DHA/yolk).
Industrially, egg yolk powder is treated with solvents
to isolate lipids and phospholipids and thereafter
the phospholipids are extracted by emulsifying with
water followed by spray-drying. A white-yellow
powder is obtained which can be easily dissolved or
emulsified in water-containing mixtures (such as
milk, yogurt, juices, etc). DHA in phospholipids is
more resistant to oxidation than in triacylglycerols
or ethyl ester (Song et al., 1997). However, natural
antioxidants (such as tocopherols) are frequently
added to preserve phospholipids from oxidation.
Interestingly, in human subjects it has been shown
that the intestinal absorption of DHA provided in the
form of egg phospholipids is greater than in the
form of triacylglycerols (Carnielli et al., 1998). Egg
yolk phospholipids can be safely included into the
mother’s diet of healthy breast-fed infants and into
infant formulas. As egg yolk contains a range of
vitamins, minerals, protein and fats, it can be
included as part of a well-balanced diet for infants
and toddlers. Egg yolk phospholipids are now an
important DHA source used in some infant formulas
in Europe and Asia. Bondía-Martínez et al. (1998)
demonstrated that infants fed formula supplemented
with 0.15% DHA and 0.30% AA from egg yolk
phospholipids provides a plasma and erythrocyte
lipid profile similar to that found in breastfed infants
during the first months of life.
sn-2 DHA monoacylglycerol
This is a new experimental source for providing
DHA supplementation. It is a monoacylglyceride
containing DHA at the sn-2 position of glycerol. The
monoacylglyceride is obtained from the controlled
enzymatic hydrolysis of highly refined salmon oil
with an immobilized fungal stereoespecific lipase
obtained from Mucor Miehei (Nieto et al., 1999).
This oil, which is obtained from the processing of
salmon-farming by-products, contains a high
proportion of DHA (22%-24%) which is almost
exclusively at the sn-2 position (85%). The
monoacylglyceride is separated from the other
products of the enzymatic hydrolysis by silver-resin
column chromatography. The monoacylglyceride
has been assayed for its absence of contaminants.
The bioavailability of the product was assayed in rats,
showing a high intestinal absorption and producing a
high DHA accretion into the brain of pups from
mothers that received DHA supplementation with the
monoacylglyceride before and during the gestation
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period (Valenzuela et al, 2005b). The product, which
contains added dl-α tocopherol as antioxidant, can
be easily incorporated into water due its emulsifying
properties that allow its incorporation into water-
containing beverages, milk, yoghurt, and also to
baked products and sausages.
7. CONCLUSIONS
Breast-feeding is the first choice in infant
nutrition. If exclusive breast-feeding is not possible
or only partially possible, infant formulas must be
the choice. Professionals who supervise newborn
nutrition are encouraged to recommend or
prescribe a number of different formulas that are
available in the market. Some of these formulas
contain LNA and LA from vegetable oils, others
contain DHA and AA which can be obtained from
the pure LC-PUFAs as ethyl esters, from single-cell
algae oils, or from egg yolk phospholipids. In the
near future some other preparations of omega-3
and omega-6 LC-PUFA will be available, such as
monoacylglycerides or modified phospholipids.
Which product is the best choice? In our opinion
more basic and clinical investigation is still
necessary to allow decisions based on scientific
evidence and supported on physiological,
biochemical, and nutritionally favourable effects. In
addition, rigorous purity and toxicological testing
should be conducted for fatty acid sources
intended for use in commercial infant formulas.
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